[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100477010":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":34,"locations":43,"responsibleParty":63,"collaborators":16,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":16,"enrollmentInfo":75,"targetDuration":16,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":46,"whyStopped":16,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Barretos Cancer Hospital","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"Post Mastectomy Hypofractionated Radiotherapy Arm","EXPERIMENTAL",[12],"Radiation: Hypofractionation",{"label":14,"type":15,"description":14,"interventionNames":16},"Post Mastectomy Conventional Radiotherapy","NO_INTERVENTION",null,[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":16},"RADIATION","Hypofractionation","Hypofractionation scheme will comprise 40 Gy in 15 fractions",[9],[24,27,30,32],{"name":25,"affiliation":5,"role":26},"Marcos D Mattos, MD, MS","PRINCIPAL_INVESTIGATOR",{"name":28,"affiliation":5,"role":29},"Gabriela B Salvador, BS","STUDY_CHAIR",{"name":31,"affiliation":5,"role":29},"Wanessa F Altei, PhD",{"name":33,"affiliation":5,"role":29},"Lais L Almeida, MD",[35,39],{"name":25,"role":36,"phone":37,"phoneExt":16,"email":38},"CONTACT","+5517981140230","marcosbtos3@gmail.com",{"name":40,"role":36,"phone":41,"phoneExt":16,"email":42},"Alexandre A Jacinto, MD, PhD","+5517974001314","jacintoaa@gmail.com",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Radiation Oncology Department","RECRUITING","Barretos","São Paulo","14784-400","Brazil","BR",{"type":53,"coordinates":54},"Point",[55,56],-48.56778,-20.55722,{"lat":56,"lon":55},[59,60],{"name":25,"role":36,"phone":37,"phoneExt":16,"email":38},{"name":40,"role":36,"phone":61,"phoneExt":62,"email":42},"+551733216600","7342",{"type":64,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100477010","hypofractionated-radiotherapy-in-breast-cancer-patients-with-prosthetic-reconstruction-100477010",false,"NCT05491395","Hypofractionated Radiotherapy in Breast Cancer Patients With Prosthetic Reconstruction","Randomized Phase III Clinical Trial of Hypofractionated Radiotherapy in Breast Cancer Patients With Immediate Prosthetic Reconstruction: PROMART Trial","PROMART","Inclusion Criteria:\n\n* Women with confirmed histological diagnosis of invasive ductal carcinoma and lobular breast carcinoma;\n* Radical mastectomy with immediate reconstruction with a prosthesis;\n* Patients indicated for adjuvant RT;\n* Any lymph node status;\n* With or without adjuvant chemotherapy;\n* ECOG performance status from 0-2;\n* \\> 18 years old;\n* Informed Consent Form applied before any study-specific procedure.\n\nExclusion Criteria:\n\n* Another histological diagnosis than invasive ductal carcinoma or lobular carcinoma;\n* Previous history of neoplasm and\u002For radiotherapy and\u002F or quimiotherapy before this study;\n* Distant metastatic disease;\n* Palliative treatment;\n* Patients with scleroderma \u002F systemic lupus erythematosus.","FEMALE","18 Years",{"count":76,"type":77},120,"ESTIMATED","INTERVENTIONAL",[80],"NA","RATIONALE:\n\nRadiotherapy (RT) can be indicated to patients submitted to breast-conserving surgery, but, despite the benefits, adjuvant RT can cause contracture generated by tissue fibrosis in patients with immediate prosthetic reconstruction, which could cause prosthesis loss. The biological explanation of this outcome is not fully understood, but recent advances in the analysis of patient-derived blood can contribute to establishing a connection of molecular alterations related to this clinical outcome.\n\nThere is not a consensus about using hypofractionated RT schemes for patients with BCS and breast reconstruction since no studies had investigated the reasons why some patients lose the prosthesis.\n\nPURPOSE: This study will evaluate G3 toxicity rate in breast cancer patients with immediate prosthetic reconstruction, submitted to hypofractionated radiotherapy, analyzing capsular contracture, leakage, infection, and bad positioning in order to demonstrate the noninferiority of Hypo-RT with the conventional RT. Additionally, the molecular profile of blood samples will be investigated in order to find biomarkers related to inflammations processes and response to treatment.",[83],"Breast Cancer",[85],"breast cancer, radiation therapy, hypofractionated, biomarkers","2022-08-04",{"date":88,"type":89},"2022-08-08","ACTUAL",{"date":91,"type":89},"2022-06-27",{"date":93,"type":77},"2029-05-01",{"name":5,"class":6},1]